Sellas Life Sciences Shares Rose After Meeting News
Investors are tracking the firm's progress in cancer studies as the company prepares for a major hematology meeting.
Updated on Oct. 12, 2026 in Cancer
Live Poll
Do you believe analyzing corporate conference booth sizes is a reliable way to guide your investments?
Sellas Life Sciences shares increased by more than 3% overnight following speculation regarding the company's upcoming presence at the American Society of Hematology meeting. This movement follows a 209% surge in stock value year-to-date as the company tracks toward Phase 2 results for its investigational drug, SLS009.
Why it matters
The company is approaching key milestones for its cancer pipeline, specifically the Regal trial and the SLS009 study, which remain under close observation by the medical and investment communities. These updates signify ongoing progress in clinical research that may eventually impact treatment options for patients with complex blood cancers.
In a lab-grown tumor model, the combination of SLS009 and Daraxonrasib produced 36.5% apoptosis and 30.6% necrosis compared to 2.8% apoptosis with the monotherapy. These results are preliminary and have not been validated in large-scale human trials.
The players
Sellas Life Sciences
A biopharmaceutical company focused on the development of novel cancer immunotherapies and targeted treatments.
American Society of Hematology
A professional organization that supports hematology research and provides a forum for scientists to share developments in blood disease treatments.
The details
The experimental drug SLS009 works by targeting specific pathways that contribute to cell survival in cancerous tumors. By pairing this agent with Daraxonrasib, researchers aim to increase programmed cell death, or apoptosis, more effectively than with either treatment alone. The company is also monitoring the Regal trial, which requires 80 total participant deaths to proceed to final analysis.
Timeline
May 11, 2026: The Regal trial reached 78 of the 80 required deaths.
August 28, 2026: The Phase 2 study for SLS009 reached its enrollment goal of 80 patients.
October 11, 2026: Sellas shares rose more than 3% overnight.
Fourth Quarter 2026: Initial results are expected for the SLS009 Phase 2 study.
December 12-15, 2026: The American Society of Hematology Annual Meeting takes place in New Orleans.
Health Landscape
This activity occurs against the backdrop of the American Society of Hematology annual meeting, which serves as a primary hub for presenting clinical oncology breakthroughs. The current focus remains on evaluating how these experimental agents perform against the existing standard of care.
These developments are currently limited to preclinical research and ongoing clinical trials, meaning they are not yet available for patient care. It is always worth discussing with your doctor how ongoing clinical trials may fit into your broader treatment strategy for blood-related conditions.
The takeaway
While preclinical lab data shows promise for combination therapies, these early findings are not yet a substitute for standard cancer treatment. Patients interested in emerging options should track future trial updates and speak with their oncologist about clinical trial enrollment criteria.
What happens next
Sellas Life Sciences is expected to provide initial results for the SLS009 Phase 2 study during the fourth quarter of 2026.
Further reading
For more information on the current state of oncology research, visit Cancer.
Source note: This article includes information reported by Asianet News Network Pvt Ltd.
Live Poll
Do you believe analyzing corporate conference booth sizes is a reliable way to guide your investments?
